A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
NCT02544997
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
5
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
Poziotinib
Sponsor
Samsung Medical Center